“Mesothelioma Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mesothelioma Market.
The Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Mesothelioma Pipeline Report:
Companies across the globe are diligently working toward developing novel Mesothelioma treatment therapies with a considerable amount of success over the years.
Mesothelioma companies working in the treatment market are The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Åslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others, are developing therapies for the Mesothelioma treatment
Emerging Mesothelioma therapies in the different phases of clinical trials are- Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others are expected to have a significant impact on the Mesothelioma market in the coming years.
In May 2026, Researchers continued enrolling patients in clinical trials evaluating mesothelin-targeted CAR-T cell therapies, bispecific antibodies, and personalized immunotherapy strategies aimed at enhancing treatment outcomes for individuals with advanced mesothelioma.
In April 2026, The ATOMIC-Meso trial assessed the efficacy of weekly intramuscular pegargiminase in combination with pemetrexed and platinum-based chemotherapy compared with placebo plus chemotherapy in previously untreated patients with mesothelioma. The study represents one of the most advanced late-stage clinical development programs for the disease.
In January 2026, Multiple Phase I–III clinical trials investigating immunotherapies, targeted therapies, CAR-T cell therapies, and tumor-targeted agents continued to enroll patients with malignant pleural mesothelioma, reflecting sustained progress in the disease's therapeutic pipeline.
In August 2025, VT3989, a TEAD autopalmitoylation inhibitor, has been granted orphan drug designation by the FDA for treating adult mesothelioma patients, as announced by Vivace Therapeutics.
In July 2025, The U.S. FDA has awarded orphan drug designation to VT3989 for mesothelioma treatment in the United States, according to Vivace Therapeutics. VT3989 is an investigational therapy that inhibits palmitoylation in TEAD proteins, key components of the Hippo pathway, which regulates cell growth and division.
In April 2025, GSK’s Zejula (niraparib) demonstrated a 27% reduction in the risk of disease progression or death in mesothelioma patients in an investigator-initiated Phase II trial. The NERO study (NCT05455424) evaluated Zejula’s effectiveness in 88 mesothelioma patients who experienced relapse following prior platinum-based systemic therapy. The trial is sponsored by the University Hospital Southampton NHS Foundation Trust and funded by Asthma + Lung UK, with additional support from Mesothelioma UK and the Mavis Nye Foundation.
In January 2025, Insilico Medicine ("Insilico"), a clinical-stage AI-driven biotechnology company, has announced that the first patient has been dosed in its global multicenter Phase I trial of ISM6331, a novel pan-TEAD inhibitor developed using its AI-powered generative chemistry platform, Chemistry42. ISM6331 is being investigated for the treatment of mesothelioma and other solid tumors. Notably, it is Insilico’s leading oncology program within its AI-driven drug discovery pipeline and has received Orphan Drug Designation (ODD) from the FDA for mesothelioma treatment.
Mesothelioma Overview
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (mesothelium). The most common form is pleural mesothelioma, which affects the lining of the lungs and is often associated with exposure to asbestos fibers. Other less common forms include peritoneal mesothelioma (affecting the lining of the abdomen), and pericardial mesothelioma (affecting the lining around the heart).
Get a Free Sample PDF Report to know more about Mesothelioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight
Emerging Mesothelioma Drugs Under Different Phases of Clinical Development Include:
Pembrolizumab: The Netherlands Cancer Institute
Nivolumab: Bristol-Myers Squibb
Durvalumab: PrECOG, LLC.
Sacituzumab govitecan-hziy: Memorial Sloan Kettering Cancer Center
Carboplatin: ETOP IBCSG Partners Foundation
Tremelimumab: MedImmune LLC
ipilimumab: Åslaug Helland
Volrustomig: AstraZeneca
OT-101: Oncotelic Inc.
Lenvatinib: Hyogo Medical University
rAd-IFN: Trizell Ltd
RSO-021: RS Oncology LLC
VT3989: Vivace Therapeutics, Inc
gavo-cel: TCR2 Therapeutics
THOR-707: Sanofi
T3011: ImmVira Pharma Co. Ltd
TC-510: TCR2 Therapeutics
CTX131: CRISPR Therapeutics
PM8002: Biotheus Inc.
Mesothelioma Route of Administration
Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Mesothelioma Molecule Type
Mesothelioma Products have been categorized under various Molecule types, such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Mesothelioma Pipeline Therapeutics Assessment
Mesothelioma Assessment by Product Type
Mesothelioma By Stage and Product Type
Mesothelioma Assessment by Route of Administration
Mesothelioma By Stage and Route of Administration
Mesothelioma Assessment by Molecule Type
Mesothelioma by Stage and Molecule Type
DelveInsight's Mesothelioma Report covers around 50+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Mesothelioma product details are provided in the report. Download the Mesothelioma pipeline report to learn more about the emerging Mesothelioma therapies
Some of the key companies in the Mesothelioma Therapeutics Market include:
Key companies developing therapies for Mesothelioma are - Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc (GSK), AbbVie Inc., Sanofi, and others.
Mesothelioma Pipeline Analysis:
The Mesothelioma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.
Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Mesothelioma drugs and therapies
Mesothelioma Pipeline Market Drivers
Rising incidence of malignant pleural mesothelioma due to historical asbestos exposure worldwide.
Increasing focus on immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and mesothelin-targeted treatments.
Strong pipeline of targeted therapies, gene therapies, and personalized medicine approaches aimed at improving patient outcomes.
Growing number of clinical trials supported by regulatory incentives such as Orphan Drug, Fast Track, and Breakthrough Therapy designations.
Mesothelioma Pipeline Market Barriers
Low disease prevalence limits patient recruitment and slows clinical trial enrollment.
Late-stage diagnosis and aggressive disease progression reduce the treatment window and clinical trial participation.
High development costs and lengthy clinical timelines for rare oncology therapies.
Limited understanding of mesothelioma biology and tumor heterogeneity complicates drug development.
Difficulty demonstrating significant survival benefits in clinical studies due to small patient populations.
Scope of Mesothelioma Pipeline Drug Insight
Coverage: Global
Key Mesothelioma Companies: The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Åslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others
Key Mesothelioma Therapies: Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others
Mesothelioma Therapeutic Assessment: Mesothelioma current marketed and Mesothelioma emerging therapies
Mesothelioma Market Dynamics: Mesothelioma market drivers and Mesothelioma market barriers
Request for Sample PDF Report for Mesothelioma Pipeline Assessment and clinical trials
Table of Contents
1. Mesothelioma Report Introduction
2. Mesothelioma Executive Summary
3. Mesothelioma Overview
4. Mesothelioma- Analytical Perspective In-depth Commercial Assessment
5. Mesothelioma Pipeline Therapeutics
6. Mesothelioma Late Stage Products (Phase II/III)
7. Mesothelioma Mid Stage Products (Phase II)
8. Mesothelioma Early Stage Products (Phase I)
9. Mesothelioma Preclinical Stage Products
10. Mesothelioma Therapeutics Assessment
11. Mesothelioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Mesothelioma Key Companies
14. Mesothelioma Key Products
15. Mesothelioma Unmet Needs
16 . Mesothelioma Market Drivers and Barriers
17. Mesothelioma Future Perspectives and Conclusion
18. Mesothelioma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679 Source: https://www.delveinsight.com/report-store.php
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/